A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

ClinicalTrials.gov ID: NCT04752332

Public ClinicalTrials.gov record NCT04752332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 12, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.

Study identification

NCT ID: NCT04752332
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 111 participants

Conditions and interventions

Conditions

Breast Neoplasms

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 9, 2021
Primary completion: Jun 25, 2024
Completion: Jun 25, 2024
Last update posted: Jul 14, 2025

2021 – 2024

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Palo Verde Cancer Specialists	Glendale	Arizona	85304	—
TRIO-US (Translational Research in Oncology-US)	Los Angeles	California	90024	—
Millennium Oncology - Hollywood	Hollywood	Florida	33024	—
Florida Cancer Specialists - North	St. Petersburg	Florida	33705	—
Mt. Sinai Hospital PRiSMS	Chicago	Illinois	60608	—
Cornell-Beshore Cancer Institute	Joplin	Missouri	64804	—
The Valley Hospital	Ridgewood	New Jersey	07450	—
Sarah Cannon Research Institute SCRI	Nashville	Tennessee	37203	—
Texas Oncology - Medical City Dallas	Dallas	Texas	75230	—
Northwest Cancer Specialists PC	The Woodlands	Texas	77380	—
Texas Oncology - Medical City Dallas	The Woodlands	Texas	77380	—
US Oncology	The Woodlands	Texas	77380	—
USO-Southern Cancer Center, P.C.	The Woodlands	Texas	77380	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04752332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 14, 2025 · Synced Sep 12, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04752332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →